ClearPoint COO Mazin settles RSUs, tax withholding

ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin reported equity award activity involving restricted stock units and common stock.

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. Chief Operating Officer Sabra Mazin reported equity award activity involving restricted stock units and common stock. On March 3, 2026, 6,642 restricted stock units were settled into the same number of shares of common stock at $0.00 per share, reflecting a scheduled vesting. In connection with this vesting, 3,380 common shares were delivered back to ClearPoint Neuro at $8.84 per share to satisfy tax withholding obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Mazin directly held 47,732 shares of common stock and 26,568 restricted stock units.

Insider Trade Summary

6,642 shares exercised/converted

Exercise 3 txns

Insider SABRA MAZIN

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	6,642	$0.00	$0.00
Exercise	Common Stock	6,642	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock	3,380	$8.84	$30K

Holdings After Transaction: Restricted Stock Units — 26,568 contracts (Direct); Common Stock — 47,732 shares (Direct)

Footnotes (2)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. F2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CLPT COO Sabra Mazin report on March 3, 2026?

Sabra Mazin reported the vesting of 6,642 restricted stock units into 6,642 shares of ClearPoint Neuro common stock and a related tax-withholding disposition of 3,380 shares, all as routine equity award activity tied to scheduled RSU vesting.

How many ClearPoint Neuro shares did Sabra Mazin hold after these Form 4 transactions?

After the reported transactions, Sabra Mazin directly held 47,732 shares of ClearPoint Neuro common stock and 26,568 restricted stock units, reflecting the net result of RSU settlement and the shares delivered to the company for tax withholding.

Were Sabra Mazin’s CLPT Form 4 transactions open-market stock purchases or sales?

No open-market trades were reported. The Form 4 shows RSU settlement into common shares at $0.00 per share and a tax-withholding disposition, where 3,380 shares were delivered to ClearPoint Neuro to cover tax obligations from the RSU vesting.

What price per share was used for Sabra Mazin’s tax-withholding disposition of CLPT stock?

The tax-withholding disposition used a price of $8.84 per share for 3,380 shares of ClearPoint Neuro common stock delivered back to the company to satisfy tax withholding obligations related to the vesting of restricted stock units.

What does each restricted stock unit in Sabra Mazin’s CLPT award represent?

Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro common stock. The Form 4 notes that the 6,642 units settled into 6,642 shares of common stock on their scheduled vesting date, consistent with the RSU terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SABRA MAZIN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		6,642	A	(1)	51,112	D
Common Stock	03/03/2026		F		3,380(2)	D	$8.84	47,732	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/03/2026		M			6,642	(1)	(1)	Common Stock	6,642	(1)	26,568	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro, by Power of Attorney for Mazin Sabra	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.